Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Mathias Hänel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Susann Schulze, MD, Song-Yau Wang, MD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2018) 132 (Supplement 1): 83.

https://doi.org/10.1182/blood-2018-99-115790

Published: 2018

Journal Articles

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, Mathias Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schultze, MD, Song-Yau Wang, MD, Oana Brosteanu, PhD, Dietger Niederwieser, MD

Blood (2015) 126 (23): 1346.

https://doi.org/10.1182/blood.V126.23.1346.1346

Published: 2015

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Nadja Jaekel, MD, Song-Yau Wang, MD, Rainer Krahl, PhD, Karolin Hubert, Susann Schulze, MD, Rayk Stengel, PhD, Melanie Schneider, Martin Roskos, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali, MD

Blood (2015) 126 (23): 2014.

https://doi.org/10.1182/blood.V126.23.2014.2014

Published: 2015

Journal Articles

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

Madlen Jentzsch, MD, Elena Ruschpler, Sabine Leiblein, PhD, Yvonne Remane, Jan-Phillip Stümpel, MD, Georg-Nikolaus Franke, MD, Simone Heyn, MD, Nadja Jaekel, MD, Susann Schulze, MD, Song-Yau Wang, MD, Wolfram Poenisch, MD, Claudia Nehring, MD, Sebastian Schwind, MD, Dietger Niederwieser, MD, Vladan Vucinic, MD

Blood (2015) 126 (23): 5439.

https://doi.org/10.1182/blood.V126.23.5439.5439

Published: 2015

Journal Articles

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Oliver Pelz-Ackermann, Michael W.N. Deininger, PhD, Michael Cross, PhD, Kathrin Wildenberger, Rainer Krahl, PhD, Song-Yau Wang, MD, Haifa K. Al-Ali, MD, Dietger W. Niederwieser, MD, Thoralf Lange, MD

Blood (2007) 110 (11): 2918.

https://doi.org/10.1182/blood.V110.11.2918.2918

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Email alerts

ASH Publications

American Society of Hematology

Update search

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only